ArticleJTO clinical and research reports2023

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices.

Stephen V Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.